{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:48:53Z","timestamp":1773683333698,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.canlet.2013.07.024","type":"journal-article","created":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T15:47:59Z","timestamp":1374853679000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models"],"prefix":"10.1016","volume":"339","author":[{"given":"Ke-Wang","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Hay","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace G.L.","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle Y.Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing-Sum","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia K.M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Ting","family":"Shum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Pui","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping-Chung","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Evdokiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara B.S.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2013.07.024_b0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2013.07.024_b0015","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1677\/ERC-09-0012","article-title":"Mechanisms of bone metastases of breast cancer","volume":"16","author":"Suva","year":"2009","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ncponc1066","article-title":"Metastasis: a therapeutic target for cancer","volume":"5","author":"Steeg","year":"2008","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"10.1016\/j.canlet.2013.07.024_b0025","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ijc.25051","article-title":"Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model","volume":"127","author":"Labrinidis","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.canlet.2013.07.024_b0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/bcr412","article-title":"Direct effects of bisphosphonates on breast cancer cells","volume":"4","author":"Senaratne","year":"2002","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2013.07.024_b0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S8756-3282(03)00223-0","article-title":"Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis","volume":"33","author":"Evdokiou","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.canlet.2013.07.024_b0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.canlet.2013.07.024_b0050","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1158\/1535-7163.MCT-09-0462","article-title":"Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone","volume":"8","author":"Ottewell","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2013.07.024_b0055","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.07.024_b0060","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/pgmj.2008.076349","article-title":"Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates","volume":"85","author":"Ryan","year":"2009","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.canlet.2013.07.024_b0065","first-page":"674","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"85","author":"Green","year":"2010","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.canlet.2013.07.024_b0070","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2010.1360","article-title":"Atypical fractures as a potential complication of long-term bisphosphonate therapy","volume":"304","author":"Sellmeyer","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.canlet.2013.07.024_b0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1517\/14740338.6.3.305","article-title":"The safety of zoledronic acid","volume":"6","author":"Lipton","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.canlet.2013.07.024_b0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.07.024_b0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/1471-2407-11-403","article-title":"Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving \u201cmetronomic\u201d zoledronic acid","volume":"11","author":"Zhao","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10549-010-1183-6","article-title":"Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance","volume":"124","author":"Zhao","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2013.07.024_b0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4161\/cbt.10.6.12611","article-title":"Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial","volume":"10","author":"Facchini","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2013.07.024_b0100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"994","author":"Daubine","year":"2007","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.canlet.2013.07.024_b0105","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/1535-7163.MCT-09-0745","article-title":"Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer","volume":"8","author":"Zinonos","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2013.07.024_b0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","article-title":"Metronomic chemotherapy: changing the paradigm that more is better","volume":"16","author":"Scharovsky","year":"2009","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2013.07.024_b0115","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2013.07.024_b0120","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.07.024_b0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-6-225","article-title":"Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer","volume":"6","author":"Orlando","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0300-2977(01)00140-1","article-title":"Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma","volume":"59","author":"De Weerdt","year":"2001","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.canlet.2013.07.024_b0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/1471-2407-9-388","article-title":"Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network","volume":"9","author":"Brizzi","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2013.07.024_b0140","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","article-title":"A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer","volume":"27","author":"Kieran","year":"2005","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2013.07.024_b0145","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","article-title":"Redefining the target: chemotherapeutics as antiangiogenics","volume":"19","author":"Miller","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.07.024_b0150","first-page":"2807","article-title":"Prolonged tumor dormancy by prevention of neovascularization in the vitreous","volume":"36","author":"Brem","year":"1976","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2013.07.024_b0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-006-0347-x","article-title":"A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma","volume":"60","author":"Krzyzanowska","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2013.07.024_b0160","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2013.07.024_b0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2013.07.024_b0170","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J. Dent. Res."},{"issue":"4","key":"10.1016\/j.canlet.2013.07.024_b0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10585-011-9377-9","article-title":"Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice","volume":"28","author":"Wolfe","year":"2011","journal-title":"Clin. Exp. Metastasis"},{"issue":"2","key":"10.1016\/j.canlet.2013.07.024_b0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.canlet.2013.07.024_b0185","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/CAD.0b013e328355f0ec","article-title":"Low-dose zoledronic acid reduces spinal cord metastasis in pulmonary adenocarcinoma with neuroendocrine differentiation","volume":"23","author":"Li","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"8","key":"10.1016\/j.canlet.2013.07.024_b0200","first-page":"822","article-title":"Amplification of \u03b3\u03b4 T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate","volume":"28","author":"Li","year":"2012","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.canlet.2013.07.024_b0195","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513005442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513005442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:17:56Z","timestamp":1715775476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513005442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0304383513005442"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.07.024","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}